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Abstract
Methicillin-resistant Staphylococcus aureus is increasingly responsible for staphylococcal infections in the community. A large percentage
of the community-acquired methicillin-resistant (CA-MRSA) strains in the USA produce Panton–Valentine leukocidin (PVL), which is
associated with severe infections. The virulence of the clinical CA-MRSA strain USA300 was compared to that of its isogenic pvl-deleted
mutant, and it was shown that PVL contributes to lung and muscle tissue destruction, respectively, in murine necrotizing pneumonia
and skin infection models. Mice infected with the USA300 strain developed a dominant anti-PVL response. The PVL subunits were
therefore tested as vaccinogens against this isolate, and their vaccine efﬁcacy correlated with both the route of vaccination and infec-
tion. These data suggest that PVL is a virulence factor in murine CA-MRSA infections.
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Introduction
Staphylococcus aureus is an opportunistic pathogen that colonizes
the skin of approximately 20–30% of the population and can
cause a diverse spectrum of disease in humans [1]. In the
last decade, steadily growing numbers of community-acquired
methicillin-resistant S. aureus (CA-MRSA) infections have been
detected globally [2–5]. Although the most frequent manifesta-
tions of CA-MRSA are skin and soft tissue infections, these
strains can cause highly invasive, rapidly progressing fatal diseases
such as necrotizing pneumonia and necrotizing fasciitis [6–11].
Three major genetic markers distinguish CA-MRSA strains
from other S. aureus strains: their genetic lineage, the com-
position of their methicillin resistance element, and the pres-
ence of the genes encoding Panton–Valentine leukocidin
(PVL). PVL is a bi-component, pore-forming toxin with the
ability to lyse leukocytes [12]. Epidemiological data, as well
as our own experimental pneumonia animal infection models,
demonstrated that PVL contributes to the severity of necro-
tizing pneumonia [13].
In contrast to recent reports, it was demonstrated, using
the clinical LAC strain and the isogenic LACDpvl mutant, that
PVL is a virulence determinant in both lung and skin murine
infection models [14,15].
The importance of PVL in the infection process was fur-
ther highlighted by immunization studies (either intranasally
or intradermally) that demonstrated that LukS-PV conferred
protection against CA-MRSA challenge (unpublished observa-
tions).
Materials and Methods
Bacterial strains and culture
S. aureus strains LAC (USA300) and LACDpvl were gener-
ously provided by F. DeLeo. Isolates were cultured aerobi-
cally on blood agar at 37C overnight, and then in 5 mL of
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casein hydrolysate and yeast extract medium (CCY) or tryp-
tic soy broth (TSB) at 37C as previously described [13].
Murine lung and skin infections
Animal experiments were carried out with 6-week-old
female Balb/c mice (Harlan, Indianapolis, IN, USA), in accor-
dance with the National Institute of Health guidelines, and
were approved by the Institutional Animal Care Use Com-
mittee at the Texas A&M HSC Institute of Biosciences and
Technology. Lung infections were induced as previously
described [13]. For the skin infections, the lower back of the
animals was shaved and cleaned with 70% ethanol; they were
then anaesthetized [13], and injected intradermally with
S. aureus (1–3 · 107 bacteria in 50 lL). Survival data were
analysed with a two-sided Fisher’s exact test with the Yates
continuity correction; weight changes were analysed with an
unpaired t-test with Welch correction.
Tissue histology and serological analysis
Mouse lungs were perfused with formalin as previously
described [13]. For the skin infection model, the skin and
muscle regions surrounding the infected site were processed
as previously described [13]. IgG-speciﬁc serum antibody
responses to S. aureus proteins were determined by an
ELISA, as previously described [16]. S. aureus proteins (Efb27–
166 [17], Map1950–237 [18], FnbpA620–881 [19], CNA3530–331
[20], SdrC182–496, SdrD50–600, SdrE51–606, ClfA229–545 [21],
ClfB201–542 [22], LukS-PV29–312 [13] and LukF-PV35–325 [13])
were expressed as His-tagged recombinant fragments, with
the exception of FnbpA, which was expressed using the
pGEX-2T vector.
Immunizations
Balb/c mice were immunized with either recombinant LukF-
PV, LukS-PV, DbpA (a Borrelia burgdorferi adhesin used as a
control antigen), toxoided alpha toxin or adjuvant alone.
Puriﬁed alpha toxin (List Biological Laboratories, Inc., Camp-
bell, CA, USA) was toxoided with formaldehyde (0.2%, w/v)
as previously described [23]. The recombinant forms of
LukF-PV, LukS-PV and DbpA were expressed as previously
described [13,24].
Intranasally vaccinated mice were immunized once per
week prior to infection on day 35. The ﬁrst immunization
was performed with 10 lg of antigen mixed with 3 lg of
cholera toxin (CT) (List Biological Laboratories), and subse-
quent vaccinations were performed with 5 lg of antigen
mixed with 1 lg of CT (10 lL).
Subcutaneously vaccinated mice were immunized twice
prior to infection on day 35 [16]. The ﬁrst immunization in
complete Freund’s adjuvant (Sigma, St. Louis, MO, USA) was
done with either 20 lg of a single antigen or 10 lg of LukF
and 10 lg of LukS administered ventrally on the right and
left sides, respectively, and boosted at day 14 in incomplete
Freund’s adjuvant (IFA) using the same amounts of antigen
(100 lL/ﬂank) [16].
Antibody proﬁle analysis
Isotype-speciﬁc biotin-conjugated rat anti-IgG1 (clone A85-1),
anti-IgG2a (clone R19-15), anti-IgG2b (clone R12-3), anti-IgG3
(clone R40-82), anti-IgE (clone R35-72), anti-IgM (clone II/41)
(BD Biosciences Pharmingen, San Jose, CA, USA) or biotiny-
lated polyclonal goat anti-mouse IgA (SBA104004) (Accurate
Chemical, Westbury, NY, USA) were used to identify iso-
type-speciﬁc serum antibody responses to either recombi-
nant LukF-PV or LukS-PV by ELISA as previously described
[16]. Serum from each mouse was taken at 0 and 28 days
post-immunization, diluted 1 : 100, and added (100 lL/well)
to the respective wells [16]. Differences in absorbance values
were analysed using the unpaired t-test [16].
Delayed-type hypersensitivity (DTH) analysis
Prior to infection with S. aureus, mice were challenged with
2.5 lg of either LukF (right footpad) or LukS (left footpad)
diluted in 50 lL of phosphate-buffered saline (PBS). Footpads
were measured at 0 and 24 h post-challenge as previously
described [18]. Differences in footpad swelling were analysed
using the unpaired t-test with Welch correction [16].
Results
The expression of PVL is linked to disease severity
Mice were infected with 1 · 108 CFUs of LAC or LACDpvl
and examined for 8 days. Seventy-two per cent of mice
(n = 57) infected with the LAC pulse-ﬁeld type isolate died
2 days post-infection, as compared to 19% of mice (n = 32)
infected with the LACDpvl isogenic mutant (p <0.0001). Mor-
tality rates did not change after day 2 post-infection (Fig. 1).
To evaluate disease progression, 5 · 107 CFUs were used
in subsequent experiments. LAC-infected mice were lethar-
gic, had hunched posture and laboured breathing, and lost
14% of their body weight during the ﬁrst 48–72 h as com-
pared to 8.5% weight loss in LACDpvl-infected mice (Fig. 2a).
As mice were most severely ill 48 h post-infection, this time-
point was chosen for histological and gross analysis of lung
tissue. Lung damage was greater in LAC-infected mice than
in LACDpvl-infected controls (Fig. 2b,c). To assess tissue
damage, a histological grading system was used where a
score of 0 represents no inﬂammation and a score of 5 rep-
resents severely damaged and inﬂamed tissue [13]. Histologi-
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cal scores were 3.42 ± 0.23 (n = 7) and 2.83 ± 0.09 (n = 6)
for LAC-infected (Fig. 2d) and LACDpvl-infected (Fig. 2e)
mice, respectively (p <0.024, Student’s t-test).
In parallel experiments, mice were infected intradermally
(1 · 107 CFUs) with LAC or LACDpvl [14]. Symptoms of
disease, including rufﬂed coat, lethargy and weight loss, were
observed as early as 24 h post-infection in the LAC-infected
mice. This group lost an average of 9% of their total body
weight during the ﬁrst 48–72 h, as compared to a 5% loss in
LACDpvl-infected mice (Fig. 2f). Regardless of the infecting
strain, mice developed an initial blister at the site of inocula-
tion (Fig. 2g,h); however, mice infected with LAC (but not
with LACDpvl) had developed severe myositis beneath the
infection site by day 7 post-infection (Fig. 2i,j, respectively).
Histological analysis of the skin and muscle tissues harvested
from the infection site of LAC-infected mice showed a
strong inﬂammatory cell inﬁltrate visualized as dark blue
aggregates throughout the tissue. Necrosis of the skin and
underlying muscle layers was also evident (Fig. 2k). Staphylo-
coccal aggregates were also visible in the fascia, dermis, epi-
dermis, and particularly at the base of the hair follicles
(Fig. 2k). In contrast, tissues harvested from LACDpvl-
infected mice had reduced inﬂammatory inﬁltrates (Fig. 2l),
which correlated with the CFUs in these tissues (Fig. S1).
To understand the nature of the immune response during
the course of a persistent skin infection, antibody reactivity
to a panel of S. aureus proteins was measured 28 days after
skin inoculation with LAC or LACDpvl (Fig. 3). Representa-
tive cell wall-anchored and secreted proteins known to be
involved in staphylococcal adherence, toxicity or immune
evasion were examined, including the collagen adhesin CNA
as a negative control, as this protein is not encoded in the
LAC genome. This analysis demonstrated that mice intrader-
mally infected with LAC developed signiﬁcant and dominant
responses to the LukS-PV subunit of PVL. Detectable IgG
reactivity was also observed against LukF-PV, the immuno-
modulator Map, alpha toxin and the complement-binding
protein Efb. LACDpvl elicited a similar response except that
there was no response to PVL.
Subcutaneous vaccinations
Mice were immunized subcutaneously (Fig. 4) with recombi-
nant PVL subunits (delivered individually or together) or with
inactivated alpha toxin. The non-staphylococcal His-tagged
negative control protein DbpA and mice treated with Fre-
und’s adjuvant alone or non-immunized were used as con-
trols. The humoral immune responses to recombinant LukF-
PV or LukS-PV were measured in mice immunized with the
different antigen formulations. On day 28 post-immunization,
mice from all vaccine groups were bled and the sera were
analysed by ELISA to detect different isotypes reactive to
either LukF-PV or LukS-PV (Fig. 4a). In addition, six mice
from each vaccination group were challenged in contralateral
footpads with either LukF-PV or LukS-PV for DTH analysis
(Fig. 4b).
Isotype proﬁle analysis revealed a dominant and speciﬁc
IgG1 anti-LukF-PV and anti-LukS-PV response following sub-
cutaneous vaccination with the respective recombinant PVL
components (Fig. 4a). Mice immunized with a single compo-
nent had an IgG1 response similar to that seen in mice
immunized subcutaneously with both components (data not
shown and Fig. 4a). The IgG2a and IgG2b responses were not
as robust as the IgG1 response; IgG2b responses were signiﬁ-
cantly greater to LukS-PV than to LukF-PV, and in the group
immunized with both subunits, the IgG2a response to LukS-
PV was greater than that to LukF-PV (Fig. 4a). IgG3, IgM or
IgE reactivity was not observed (Fig. 4a and data not shown).
The DTH response to LukF-PV or LukS-PV demonstrated
that immunization with either LukF-PV or LukS-PV resulted in
a speciﬁc response to each respective component (Fig. 4b).
The DTH response to the PVL components in the subcutane-
ously immunized mice paralleled the IgG2b antibody response
described above, and mice that received equal amounts of
both components developed a dominant anti-LukS-PV res-
ponse. Mice immunized with control proteins (alpha toxin or
DbpA) or adjuvant alone did not develop a signiﬁcant response
when compared to the challenge-only (untreated) group, dem-
onstrating that neither the control proteins nor adjuvant alone
elicited a cross-reactive LukF-PV or LukS-PV response.
The route of vaccination correlated with vaccine efﬁcacy
in the context of the type of infection studied. Immunized
animals were inoculated with bacterial suspensions intrana-
sally or intradermally to determine the efﬁcacy of the vaccine
FIG. 1. Pneumonia survival curve. Balb/c mice were intranasally
inoculated with a suspension of 1–3 · 108 CFUs of either Staphylo-
coccus aureus USA300 LAC (•) or S. aureus LACDpvl ( ). Mortality
was recorded at 24 and 48 h post-infection, and animals were moni-
tored for up to 7 days.
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FIG. 2. Panton–Valentine leukocidin-deleted mutants cause less severe infections. (a–e) Mice were infected intranasally with 3–5 · 107 CFUs of
each Staphylococcus aureus strain, LAC (•) or LACDpvl (o). (a) Weight loss in grams over time (days). (b, c) Gross lung morphology 2 days post-
infection (b, LAC; c, LACDpvl). (d, e) Five-micrometre lung sections were stained with haematoxylin and eosin (H&E), ·20 magniﬁcation. (f–l)
Mice were infected intradermally with 1 · 107 CFUs of each S. aureus strain, LAC ( ) or LACDpvl (h). (f) Weight loss in grams over time
(days). (g, h) Gross superﬁcial skin morphology. Intradermally infected animals were killed and photographed 7 days post-inoculation (g, LAC; h,
LACDpvl). (i, j) Gross morphology of tissues underlying the infection site (i, LAC; j, LACDpvl). (k, l) Five-micrometre tissue sections stained with
H&E, 10· magniﬁcation.
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formulations against either lung or skin infections (Fig. 4c,d).
For each immunization group, mortality and weight loss were
assessed 8 and 14 days post-infection, respectively. Subcuta-
neously administered LukF-PV and LukS-PV (LukFS) may have
resulted in a more effective immune response, as mice receiv-
ing either a multicomponent formulation of LukFS or alpha
toxin were better protected; however, the differences in the
pneumonia challenge were not statistically signiﬁcant over
the complete Freud’s adjuvant CFA-only control (Fig. 4c).
Although 60–55% of mice vaccinated with LukF-PV-CFA or
LukS-PV-CFA survived 8 days post-infection, as compared to
13.3% of the infection-only group (p 0.01 and p 0.03), when
these animals were compared to the DbpA-only or CFA-only
groups, the differences were not signiﬁcant (Fig. 4c).
In addition to the pneumonia challenge, the effectiveness
of the different vaccination strategies against a non-lethal,
intradermal infection was examined, which allowed the moni-
toring of weight loss as a measure of chronic disease over a
2-week period (Fig. 4d).
The protective effect of subcutaneously administered LukF-
PV-CFA or LukS-PV-CFA, as compared to the infection-only
or the CFA-only control groups, was apparent as early as
day 3 post-infection (p <0.0003, unpaired t-test) and remained
statistically different through day 14 post-infection (Fig. 4d).
Mucosal vaccinations
Mice were intranasally immunized with either LukF-PV, LukS-
PV or alpha toxin with CT as an adjuvant. Administration of
both LukF-PV and LukS-PV intranasally resulted in signiﬁcant
inﬂammation of the respiratory epithelium even if they were
administered 2 days apart (data not shown); therefore, a
multicomponent approach was not viable for this vaccination
route. However, each subunit administered independently
was well tolerated. Control animals received DbpA or PBS
mixed with CT. As observed for subcutaneously vaccinated
animals, intranasally immunized mice developed a dominant
IgG1 anti-LukF-PV and anti-LukS-PV response (Fig. 5a). Both
LukF-PV and LukS-PV intranasally vaccinated mice had ele-
vated IgG2a responses; IgG2b responses were signiﬁcantly
greater to LukS-PV than to LukF-PV (Fig. 5a). IgG3, IgM or
IgE reactivity was not detected in the sera obtained from
any of the vaccination groups (Fig. 5a and data not shown).
The only isotype detected in the sera of intranasally vacci-
nated groups (LukS-PV-vaccinated mice only) that was not
observed in subcutaneously vaccinated groups was IgA
(Fig. 5a).
The cellular response to LukF-PV or LukS-PV demon-
strated that intranasal immunization with either component
resulted in a speciﬁc, respectively, response (Fig. 5b) as
described for intradermally immunized mice.
The intranasal vaccination was very effective in protecting
mice against pneumonia; mice vaccinated with LukS-PV were
signiﬁcantly protected against an intranasal challenge (75%
survival at day 8 post-infection; p <0.0001) when compared
to the infection-only, DbpA or adjuvant-only controls
(13.3%, 26.6% and 6.9% survival, respectively, at day 8 post-
infection) and they were signiﬁcantly protected (p <0.05)
when compared to LukF-PV-vaccinated mice or mice intrana-
sally vaccinated with alpha toxin (48.3% and 43.7% survival,
respectively, at day 8 post-infection) (Fig. 5c). The animals
vaccinated with LukF-PV and alpha toxin were also signiﬁ-
cantly protected as compared to the control groups
(p <0.005 and p <0.02) (Fig. 5c), although these components
were less effective than LukS-PV.
In contrast, intranasally vaccinated mice were not well
protected against intradermal challenge, as weight differences
in LukF-PV- or LukS-PV-vaccinated mice were only apparent
at days 14–15 post-infection (p <0.001 and p <0.04) (Fig 5d).
Discussion
Because the severity of CA-MRSA infections has been linked
to strains expressing the pvl determinant, disease presenta-
tion was examined in mice infected either intranasally or
FIG. 3. Antibody response to virulence factors. Mice were infected
intradermally with 1 · 107 CFUs of either Staphylococcus aureus LAC
or S. aureus LACDpvl. Twenty-eight days later, sera from ﬁve mice
were collected, and the reactivity of antibodies towards selected
recombinant S. aureus virulence factors was tested. CNA was used as
a negative control, as it is not encoded in the S. aureus USA300 gen-
ome. The presence of antibodies from groups of ﬁve animals infected
with LAC (•), infected with LACDpvl (,) or uninfected ( ), that were
reactive to the S. aureus virulence factors was tested using ELISA as
previously described. Each symbol represents the response of each
animal. The data are expressed as the mean ± SD of three wells.
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intradermally with either LAC or LACDpvl, and the hypothe-
sis that vaccination with the PVL components could protect
against LAC infections was tested [4,25,28]. Before this was
done, the functionality of LAC PVL was checked by compar-
ing the kinetics of propidium iodide incorporation into poly-
morphonuclear neutrophils treated with supernatants from
LAC vs. LACDpvl cultures (Fig. S2). The importance of anti-
PVL immunity in protection against LAC infections (of lung
or skin) was strengthened by the observations that mice
infected with LAC presented with more severe disease mani-
festations than mice infected with LACDpvl. These data
appear to contradict recent experiments, carried out in a
superﬁcially similar infection model, which led to the conclu-
sion that PVL is not a virulence determinant in murine infec-
tions [15,29,30]. However, signiﬁcant technical differences
exist between the models that may explain the different con-
clusions reached by Wardenburg et al. [15]. First, in the skin
model, assessing the role of PVL by measuring the lesion size
following an intradermal inoculation is insufﬁcient. Intrader-
mal infection in the present model also revealed no differ-
FIG. 4. Subcutaneous immunizations. (a) Isotype proﬁle analysis following vaccination. Twenty-eight days following a subcutaneous immunization
regimen with either LukF or LukS (or LukF and LukS in one group of subcutaneously vaccinated mice), mice were bled and their sera were anal-
ysed for isotype-speciﬁc (IgG1, IgG2a, IgG2b, IgG3, IgE, IgA, or IgM) anti-LukF or anti-LukS responses. Only IgG1-, IgG2a-, IgG2b- and IgA-speciﬁc
antibodies were detected. The IgG3 response is representative of negative responses, i.e. IgE and IgM. The number of mice used in each treat-
ment group is indicated in parentheses. Each symbol represents the mean ± SE response within each group. p <0.05, IgG2a anti-LukS response
as compared to the IgG2a anti-LukF response in subcutaneously vaccinated mice; unpaired t-test with Welch correction. (b) Delayed-type hyper-
sensitivity response to LukF and LukS following vaccination. Thirty-four days post-vaccination, mice from all groups were challenged on the right
and left footpads with 2.5 lg of LukF and LukS, respectively. Footpads were measured at 0 and 24 h after challenge, and the response to LukS
(black) and to LukF (white) is expressed as the mean ± SE of six mice/group (*p <0.0001 as compared to the contralateral footpad or to the
challenge-only control; unpaired t-test with Welch correction). (c) Percent survival following intranasal inoculation with Staphylococcus aureus
USA300. Balb/c mice (total numbers used/group indicated in parentheses) were vaccinated subcutaneously with recombinant LukF, LukS, control
proteins or adjuvant alone prior to infection with 5 · 107 CFUs of S. aureus in a volume of 20 lL. Mouse survival was monitored for up to 7 days
post-infection. (d) Weight change in vaccinated mice following intradermal infection. Vaccinated mice were intradermally infected with S. aureus
USA300 and weighed before and after infection. Symbols represent the weight loss in mice vaccinated with LukS (•), LukF ( ), CFA only (.), or
unvaccinated (s). p <0.01 LukF- and LukS-vaccinated mice as compared to CFA-only-vaccinated groups of mice; unpaired t-test with Welch
correction.
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ences in superﬁcial wound size; however, mice infected with
LAC developed severe, deep myositis beneath the infection
site that was nearly absent in LACDpvl-infected mice. These
differences can only be appreciated by observing the depth
of the lesions by analysis of gross morphology and histology.
Second, the pneumonia model results are questionable, as
the number of CFUs obtained 2 days after infection are
much lower than expected, based on similar experiments
carried out in the present model. These data suggest that
the mice may not have been properly infected. In addition,
when mice are inoculated via the left nostril, most of the
inoculum enters into the left lung; that is, the inoculum is
not equally distributed to both lobes. Therefore, drawing
conclusions regarding the infectivity of LAC inoculated via
the left nostril by determining the CFUs from the right lobe
[15] does not accurately reﬂect infection of the entire lung.
Third, the intranasal administration of almost any bacte-
rium results in some degree of lung inﬂammation; it is there-
fore not surprising that inﬂammation was observed in mice
infected with either LAC or LACDpvl. However, to clearly
discern degrees of inﬂammation resulting from LAC or
LACDpvl infections, the lungs must be ﬁxed by perfusing and
FIG. 5. Mucosal immunizations. (a) Isotype proﬁle analysis following vaccination. Twenty-eight days following a intranasal immunization regimen
with either LukF or LukS (or control proteins), mice were bled and their sera were analysed for isotype-speciﬁc (IgG1, IgG2a, IgG2b, IgG3, IgE,
IgA, or IgM) anti-LukF or anti-LukS responses. Only IgG1-, IgG2a-, IgG2b- and IgA-speciﬁc antibodies were detected. The IgG3 response is repre-
sentative of negative responses, i.e. IgE and IgM. The number of mice used in each treatment group is indicated in parentheses. Each symbol rep-
resents the mean ± SE response within each group. p <0.005, IgG2b and IgA anti-LukS response as compared to the IgG2b and IgA anti-LukF
response in intranasally vaccinated mice; unpaired t-test with Welch correction. (b) Delayed-type hypersensitivity response to LukF and LukS fol-
lowing vaccination. Thirty-four days post-vaccination, mice from all groups were challenged on the right and left footpads with 2.5 lg of LukF
and LukS, respectively. Footpads were measured at 0 and 24 h after challenge, and the response to LukS (black) and to LukF (white) is
expressed as the mean ± SE of six mice/group (*p <0.0001 as compared to the contralateral footpad or to the challenge-only control; unpaired
t-test with Welch correction). (c) Percent survival following intranasal inoculation with Staphylococcus aureus USA300. Balb/c mice (total numbers
used/group indicated in parentheses) were vaccinated subcutaneously with recombinant LukF, LukS, control proteins or adjuvant alone prior
to infection with 5 · 107 CFUs of S. aureus in a volume of 20 lL. Mouse survival was monitored for up to 7 days post-infection. The percent
survival of mice immunized intranasally with LukS was signiﬁcantly different when compared to LukF-, DbpA- and alpha toxin-immunized mice
(p <0.05) or to non-immunized mice (p <0.0001; Fisher’s exact test). (d) Weight change in vaccinated mice following intradermal infection.
Vaccinated mice were intradermally infected with S. aureus USA300 and weighed before and after infection. Symbols represent the weight loss in
mice vaccinated with LukS (•), LukF ( ), cholera toxin (CT) only ( ), or unvaccinated (s).
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inﬂating them with formaldehyde to preserve tissue struc-
tures normally ﬁlled with air (such as alveolar spaces). This is
not a minor point, as the procedure facilitates the discern-
ment of differences in tissue damage, oedema and inﬂamma-
tion resulting from infection by the different strains. As
shown by Wardenburg et al. [15], the morphology of a col-
lapsed lung pictured at low magniﬁcation is difﬁcult to inter-
pret. Fourth, when evaluating LAC-derived strains, weight
loss data over a 2-day period are not sufﬁcient to allow
weight differences to manifest [15], as opposed to a 7–14-
day period post-infection, monitored for both lung- and skin-
infected mice, as reported in this study. Fifth, the age and
weight of the mice used in the infection studies also play sig-
niﬁcant roles in disease presentation. The data shown in this
article were obtained from 6-week-old infected mice. Finally,
although we have performed experiments in which LAC cul-
tures were grown in both TSB and CCY media with similar
results, the strains used in this study were cultured in CCY
medium as opposed to the TSB medium used by other inves-
tigators [15,29]. This may be signiﬁcant, as the production of
PVL is greatly enhanced when strains are grown in CCY
rather than TSB medium.
The data presented in this article demonstrate that PVL is
linked to disease severity in murine models of pneumonia
and cutaneous infection, and that the LukS-PV subunit admin-
istered intranasally protects mice against LAC-induced pneu-
monia but not against intradermal infection.
In contrast, mice subcutaneously vaccinated with LukF-PV
and LukS-PV were protected against an intradermal infection
but not against a pulmonary infection. The primary difference
between the mice vaccinated intranasally with LukS-PV and
the groups that received other vaccines was the generation
of anti-LukS-PV IgA, which may explain the signiﬁcant protec-
tive effects of this formulation against lung but not skin chal-
lenge.
The antigenic dominance of LukS-PV was also observed in
the subcutaneously vaccinated mice, as a dominant anti-LukS-
PV IgG2a, IgG2b and DTH response in mice immunized with
both components suggested that the immune response to
LukS-PV was most likely associated with protection.
In summary, these data demonstrate the importance of
the immunization route with regard to diminishing speciﬁc
disease manifestations caused by the same pathogen and that
humoral responses resulting from intranasal or subcutaneous
vaccination directed at the LukS-PV component could pro-
tect mice accordingly against either a pulmonary or an intra-
dermal infection.
Finally, these data demonstrate that the murine model is a
valid tool for evaluating the role of PVL in disease when per-
formed carefully.
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